MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

REVOLUTION Medicines Inc

Suletud

SektorTervishoid

38.3 -1.85

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

38.2

Max

39.44

Põhinäitajad

By Trading Economics

Sissetulek

-19M

-213M

Aktsiakasum

-1.13

Kasumimarginaal

-74.379

Töötajad

616

EBITDA

-24M

-237M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+79.82% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-437M

7.1B

Eelmine avamishind

40.15

Eelmine sulgemishind

38.3

Uudiste sentiment

By Acuity

61%

39%

319 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

REVOLUTION Medicines Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. juuli 2025, 21:01 UTC

Tulu

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

18. juuli 2025, 20:46 UTC

Tulu

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18. juuli 2025, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. juuli 2025, 20:36 UTC

Tulu

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18. juuli 2025, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18. juuli 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. juuli 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18. juuli 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18. juuli 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18. juuli 2025, 18:24 UTC

Tulu

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18. juuli 2025, 18:19 UTC

Tulu

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18. juuli 2025, 18:11 UTC

Omandamised, ülevõtmised, äriostud

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18. juuli 2025, 18:11 UTC

Tulu

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18. juuli 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18. juuli 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18. juuli 2025, 16:28 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. juuli 2025, 16:22 UTC

Tulu

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Financial Services Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

18. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. juuli 2025, 16:04 UTC

Tulu

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18. juuli 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18. juuli 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18. juuli 2025, 15:47 UTC

Market Talk
Tulu

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Võrdlus sarnastega

Hinnamuutus

REVOLUTION Medicines Inc Prognoos

Hinnasiht

By TipRanks

79.82% tõus

12 kuu keskmine prognoos

Keskmine 70.22 USD  79.82%

Kõrge 80 USD

Madal 57 USD

Põhineb 10 Wall Streeti analüütiku instrumendi REVOLUTION Medicines Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

10

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

40.67 / 41.96Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

319 / 376 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.